Efficacy of tezepelumab in patients with severe, uncontrolled asthma, according to baseline blood eosinophil count and allergic status: results from the phase 3 NAVIGATOR study

被引：0

作者：

Menzies-Gow, A. ^{[1
]}

Corren, J. ^{[2
]}

Cook, B. ^{[3
]}

Kmita, K. ^{[4
]}

Llanos-Ackert, J. ^{[5
]}

Colice, G. ^{[6
]}

Ambrose, C. S. ^{[3
]}

机构：

[1] Royal Brompton Hosp, London, England

[2] Univ Calif Los Angeles UCLA, David Geffen Sch Med, Los Angeles, CA USA

[3] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Gaithersburg, MD USA

[4] AstraZeneca, BioPharmaceut R&D, Biometr Latestage Dev Resp & Immunol, Warsaw, Poland

[5] Amgen Inc, Global Med Affairs, Thousand Oaks, CA USA

[6] AstraZeneca, BioPharmaceut R&D, Latestage Dev Resp & Immunol, Gaithersburg, MD USA

来源：

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

1026

引用

页码：21 / 22

页数：2